RxDoctor Payments Data

Amy Sapp, MD

Family Medicine · Winston-Salem, NCNPI 1720073711

Payments from drug & device makers

$9,184in general payments, 2019–2025

Across 614 payments — averaging $14.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$1K
  • Novo Nordisk$1K
  • AbbVie$983
  • Amgen$811
  • Lilly USA, LLC$568
  • AstraZeneca$436
  • plus $4K from 48 others

What the payments were for

  • Food & beverage$9,184100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,184 in reported general payments places this provider in the 90th percentile of 3,444 family medicine providers in North Carolina.

See all family medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$56,575
Medicare patients
135
Services billed
1,383

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide65$90,691
FarxigaDapagliflozin Propanediol48$75,578
TrulicityDulaglutide25$40,229
EliquisApixaban23$38,618
MounjaroTirzepatide27$33,285
XareltoRivaroxaban15$24,867
MyrbetriqMirabegron19$24,255
Repatha SureclickEvolocumab28$21,999
Soliqua 100-33Insulin Glargine/Lixisenatide24$21,284
ArexvyRsvpref3 Antigen/As01e/Pf62$19,258
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$17,913
TradjentaLinagliptin12$10,310
ShingrixVaricella-Zoster Ge/As01b/Pf39$8,669
SynthroidLevothyroxine Sodium62$4,324
Lantus SolostarInsulin Glargine,hum.Rec.Anlog29$4,278

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,006$90,69165 claims
AstraZenecaFarxiga$436$75,57848 claims
Lilly USA, LLCTrulicity, Mounjaro$568$73,51452 claims
GSKArexvy, Trelegy Ellipta, Shingrix$253$45,840122 claims
PfizerEliquis$1,009$38,61823 claims
Johnson & JohnsonXarelto$247$24,86715 claims
Astellas Pharma US IncMyrbetriq$305$24,25519 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$248$21,28424 claims
Boehringer IngelheimTradjenta$319$10,31012 claims
AbbVieSynthroid$983$4,32462 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,444 family medicine providers in North Carolina.

Other family medicine in Winston-Salem

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →